Home › NDC Lookup › RxCUI directory › RxCUI 2739866

Orforglipron 14.5 MG Oral Tablet [Foundayo] — RxCUI 2739866

RxNorm drug concept · Semantic branded drug
RxCUI 2739866 Semantic branded drug · SBD ● Current RxNorm concept 6 FDA products 7 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2739866
Official nameOrforglipron 14.5 MG Oral Tablet [Foundayo]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asFoundayo 14.5 MG (equivalent to orforglipron calcium 14.81 MG) Oral Tablet; Foundayo 14.5 MG Oral Tablet
FDA products mapped6
Package NDCs mapped7
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Orforglipron: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Foundayo contains orforglipron, which works the same way as other GLP-1 receptor agonist medicines — it activates receptors in your brain that control hunger, so you feel less hung...
  • What exactly is Foundayo, and how is it different from injectable weight-loss medicines?
  • The most common ones are stomach-related — nausea, constipation, diarrhea, and sometimes vomiting. These tend to be worst early on and after each dose increase, but they usually ea...
  • What side effects should I expect when I first start taking it?
📖 Read our full Orforglipron guide →

🕸️ Concept Web — How Orforglipron 14.5 MG Oral Tablet [Foundayo] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Orforglipron 14.5 MG Oral Tablet [Foundayo] RxCUI 2739866

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Orforglipron 2739838
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Foundayo 2739845
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Orforglipron Oral Tablet 2739843
    • Orforglipron Oral Product 2739841
    • Orforglipron Pill 2739842
    • Orforglipron Oral Tablet [Foundayo] 2739849
    • Foundayo Oral Product 2739847
    • Foundayo Pill 2739848
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Orforglipron 14.5 MG Oral Tablet SCD · 2739864
  • Orforglipron 14.5 MG SCDC · 2739863
  • Orforglipron Oral Tablet SCDF · 2739843
  • Orforglipron Oral Product SCDG · 2739841
  • Orforglipron Pill SCDG · 2739842

Brand-Name Concepts

  • Orforglipron 14.5 MG [Foundayo] SBDC · 2739865
  • Orforglipron Oral Tablet [Foundayo] SBDF · 2739849
  • Foundayo Oral Product SBDG · 2739847
  • Foundayo Pill SBDG · 2739848
  • Foundayo BN · 2739845

📦 FDA Products & Package NDCs

6 products · 7 package NDCs
7 package NDCs map to RxCUI 2739866 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00002-4178-31 1 BOTTLE in 1 CARTON (0002-4178-31) / 30 TABLET, FILM COATE... FOUNDAYO Eli Lilly and Company 2026-04-01
00002-4178-62 1 BOTTLE in 1 CARTON (0002-4178-62) / 30 TABLET, FILM COATE... FOUNDAYO Eli Lilly and Company 2026-04-01
00002-4503-31 1 BOTTLE in 1 CARTON (0002-4503-31) / 30 TABLET, FILM COATE... FOUNDAYO Eli Lilly and Company 2026-04-01
00002-4794-31 1 BOTTLE in 1 CARTON (0002-4794-31) / 30 TABLET, FILM COATE... FOUNDAYO Eli Lilly and Company 2026-04-01
00002-4803-31 1 BOTTLE in 1 CARTON (0002-4803-31) / 30 TABLET, FILM COATE... FOUNDAYO Eli Lilly and Company 2026-04-01
00002-4839-31 1 BOTTLE in 1 CARTON (0002-4839-31) / 30 TABLET, FILM COATE... FOUNDAYO Eli Lilly and Company 2026-04-01
00002-4953-31 1 BOTTLE in 1 CARTON (0002-4953-31) / 30 TABLET, FILM COATE... FOUNDAYO Eli Lilly and Company 2026-04-01
Observed labelers: Eli Lilly and Company (7) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.